Document:

***Text
Omitted and Filed Separately

Confidential
Treatment Requested 

Under
17 C.F.R §§ 200.80(b)(4)

And
240.24b-2

 

Exhibit
10.2

 

CONFIDENTIAL

 

THIRD Amendment to Commercial Supply Agreement for Exenatide

 

THIS THIRD AMENDMENT (“Amendment”)
is effective as of September 20, 2010 and is by and between AMYLIN PHARMACEUTICALS, INC., a
Delaware corporation (“Amylin”), having a place of business at 9360 Towne
Centre Drive, San Diego, California 92121 USA and BACHEM
AMERICAS, INC., a California corporation, having a place of
business at 3132 Kashiwa Street, Torrance, CA 95050 USA and BACHEM INC, a California corporation, having a place of
business at 3132 Kashiwa Street, Torrance, CA 
90505 (collectively “Bachem”).

 

WHEREAS,
Amylin and Bachem entered into an Agreement effective as of December 23,
2003, directed to the supply of commercial scale Exenatide, as amended (the “Commercial
Supply Agreement”));

 

WHEREAS,
Amylin and Bachem have agreed to modify the pricing and exclusivity provisions
of the Commercial Supply Agreement;

 

WHEREAS,
Amylin and Bachem have mutually agreed to modify the Specifications; and

 

NOW,
THEREFORE, in consideration of the premises above and the terms and conditions
set forth below, the parties agree as follows:

 

1.     Paragraph 2.3 is hereby
deleted and replaced with the following:

 

2.3              The price for the Product
shall be based on minimum order volumes of [***] per order, or the [***],
whichever is less, and shall be [***] ($[***]), which price shall include the
costs of Materials and analytical release testing.  If Materials’ costs or waste disposal costs
change by more than [***] percent ([***]%) over the [***], the price for the
Product may be adjusted, subject to the parties’ mutual written agreement, to
reflect the change in such costs.

 

The price is based on current specifications.  The parties agree that changes to the Product
Specifications that are set forth in Exhibit 1.1 attached herein and
incorporated by this reference dated June 16, 2010, will not result in any
change to the price set forth above; provided, however that, if such changes to
the Product Specifications reflect process capabilities that are outside the
process capabilities demonstrated by Bachem in manufacturing validation
batches, then the parties will discuss whether such price would require
adjustment as a consequence.

 

If certain process improvements can be identified, Bachem and Amylin
will jointly decide on a course of action, provided that no change to the
manufacturing process for Product may be implemented without Amylin’s prior
written approval.  Bachem will quote for
the work that implementation of changes involves.  Amylin can then elect to pursue this
option.  Any cost savings that insue from
the implementation of these changes would be [***] between the parties.

 

2.     Paragraph 3.14 is hereby
deleted in its entirety and not replaced.

 

***Confidential
Treatment Requested 

 

1

 

3. Under Article 12, “Notices” of the Agreement, contact
information is hereby deleted and replaced with the following:

 

	
  If
  to Amylin:

  	
  Amylin
  Pharmaceuticals

  
	
   

  	
  9360
  Towne Centre Drive

  
	
   

  	
  San
  Diego, CA 92121

  
	
   

  	
  Telefax
  No: 858-552-2212

  
	
   

  	
  Attn:
  Paul Marshall, Senior Vice President, Operations

  
	
   

  	
   

  
	
  With
  a copy to:

  	
  Amylin
  Pharmaceuticals

  
	
   

  	
  9360
  Towne Centre Drive

  
	
   

  	
  San
  Diego, CA 92121

  
	
   

  	
  Telefax
  No.: 858-552-1936

  
	
   

  	
  Attn:
  Marcea Bland Lloyd, Senior Vice President and General Counsel

  
	
   

  	
   

  
	
  If
  to Bachem

  	
  Bachem
  Americas, Inc.

  
	
   

  	
  3132
  Kashiwa Street

  
	
   

  	
  Torrance,
  CA 90505

  
	
   

  	
  Telefax
  No. 310-539-9428

  
	
   

  	
  Attn:
  Philip Ottiger, President & Chief Executive Officer

  
	
   

  	
   

  
	
  With
  a copy to:

  	
  Bachem, Inc.

  
	
   

  	
  3132
  Kashiwa Street

  
	
   

  	
  Torrance,
  CA 90505

  
	
   

  	
  Telefax
  No. 310-530-2426

  
	
   

  	
  Attn:
  Alex Fässler, Chief Operating Officer

  

 

4.
Except as expressly stated above, the Agreement remains in full force and
effect in accordance with its terms. 
Unless otherwise stated in this Amendment each defined term herein shall
have the same meaning ascribed to such term in the Agreement.

 

5.
The terms and conditions of this Amendment are hereby incorporated into and
made a part of the Supply Agreement.

 

2

 

IN
WITNESS WHEREOF, the parties have caused this Amendment to be executed as of
the date written above.

 

	
  Bachem Americas, Inc.

  	
   

  	
  Amylin Pharmaceuticals, Inc.

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
  By:

  	
  /s/ Philip Ottiger

  	
   

  	
  By:

  	
  /s/
  Paul Marshall

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Name:

  	
  Philip Ottiger

  	
   

  	
  Name:

  	
  Paul
  Marshall

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Tltle:

  	
  President &
  CEO

  	
   

  	
  Title:

  	
  Senior Vice President, Operations

  

 

 

	
  Bachem, Inc.

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
  By:

  	
  /s/
  Alex Fässler

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Name:

  	
  Alex
  Fässler

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Tltle:

  	
  Chief Operating Officer

  	
   

  	
   

  	
   

  

 

3

 

EXHIBIT 1.1

 

4

 

CONFIDENTIAL

 

[Amylin logo]

 

CONFIDENTIAL — Do Not Reproduce

 

Document Approval Sheet

 

	
  Document Type:

  	
  Specification

  
	
  Document Number:

  	
  SPEC-111

  
	
  Title:

  	
  Specification for AC2993 Drug
  Substance (Bachem)

  
	
  Revision Number:

  	
  10

  
	
  Supersedes:

  	
  [***]

  
	
  Dept. Owner:

  	
  [***]

  
	
  Quality Program:

  	
  [***]

  

 

Approvals

 

	
  Rami Nagola

  	
   

  	
  /s/ Rami Nagola

  	
   

  	
  LQA

  	
   

  	
  16 June 2010

  
	
  Initiator (print name)

  	
   

  	
  Signature

  	
   

  	
  Dept.

  	
   

  	
  Date

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Sharon Ho Burns

  	
   

  	
  /s/ Sharon Ho Burns

  	
   

  	
  Mfrg

  	
   

  	
  16 June 2010

  
	
  Approver (print name)

  	
   

  	
  Signature

  	
   

  	
  Dept.

  	
   

  	
  Date

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  James Shanley

  	
   

  	
  /s/ James Shanley

  	
   

  	
  PQ

  	
   

  	
  16 June 2010

  
	
  Quality Mgmt (print name)

  	
   

  	
  Signature

  	
   

  	
  Dept.

  	
   

  	
  Date

  

 

***Confidential
Treatment Requested 

 

5

 

[Amylin logo]

 

Title:  Specification for AC2993 Drug Substance
(Bachem)

 

Corporate Specification for AC2993
Drug Substance, Supplier: Bachem

 

Description:    N/A

 

	
  ATTRIBUTE

  	
   

  	
  ALERT

  LIMIT(1)

  	
   

  	
  SPECIFICATION

  	
   

  	
  METHOD

  
	
  [***](5)

  	
   

  	
  None

  	
   

  	
  [***]

  	
   

  	
  [***](2)

  
	
  [***] by [***]

  	
   

  	
   

  
	
  [***]

  	
   

  	
  None

  	
   

  	
  [***] mole ratio

  	
   

  	
   

  
	
  [***]

  	
   

  	
  None

  	
   

  	
  [***] mole ratio

  	
   

  	
   

  
	
  [***]

  	
   

  	
  None

  	
   

  	
  [***] mole ratio

  	
   

  	
   

  
	
  [***]

  	
   

  	
  None

  	
   

  	
  [***] mole ratio

  	
   

  	
   

  
	
  [***]

  	
   

  	
  None

  	
   

  	
  [***] mole ratio

  	
   

  	
   

  
	
  [***]

  	
   

  	
  None

  	
   

  	
  [***] mole ratio

  	
   

  	
   

  
	
  [***]

  	
   

  	
  None

  	
   

  	
  [***] mole ratio

  	
   

  	
   

  
	
  [***]

  	
   

  	
  None

  	
   

  	
  [***] mole ratio

  	
   

  	
   

  
	
  [***]

  	
   

  	
  None

  	
   

  	
  [***] mole ratio

  	
   

  	
  [***](2)

  
	
  [***]

  	
   

  	
  None

  	
   

  	
  [***] mole ratio

  	
   

  	
   

  
	
  [***]

  	
   

  	
  None

  	
   

  	
  [***] mole ratio

  	
   

  	
   

  
	
  [***]

  	
   

  	
  None

  	
   

  	
  [***] mole ratio

  	
   

  	
   

  
	
  [***]

  	
   

  	
  None

  	
   

  	
  [***] mole ratio

  	
   

  	
   

  
	
  [***]

  	
   

  	
  None

  	
   

  	
  [***] mole ratio

  	
   

  	
   

  
	
  [***]

  	
   

  	
  None

  	
   

  	
  [***] mole ratio

  	
   

  	
   

  
	
  [***]

  	
   

  	
  None

  	
   

  	
  [***] mole ratio

  	
   

  	
   

  
	
  [***] by [***]

  	
   

  	
  None

  	
   

  	
  [***] ± [***]

  	
   

  	
  [***](3)

  
	
  [***] by [***]

  	
   

  	
  None

  	
   

  	
  Consistent with reference
  standard

  	
   

  	
  [***](2)

  
	
  [***](5)

  	
   

  	
  NMT [***]%

  	
   

  	
  NMT [***]%

  	
   

  	
  [***](2)

  
	
  [***](5)

  	
   

  	
  None

  	
   

  	
  NMT [***]%

  	
   

  	
  [***](4)

  
	
  [***] by [***]

  	
   

  	
  NMT [***]%

  	
   

  	
  Not required

  	
   

  	
  [***](4)

  
	
  [***](5)

  	
   

  	
  NLT [***]%

  	
   

  	
  NLT [***]%

  	
   

  	
  [***](2)

  
	
  [***] by [***](5)

  	
   

  	
  NMT [***]%

  	
   

  	
  NMT [***]%

  	
   

  	
  [***](2)

  
	
  [***] by [***](5)

  	
   

  	
  None

  	
   

  	
  NMT [***]%

  	
   

  	
  [***](2)

  
	
  [***] by [***](5)

  	
   

  	
  None

  	
   

  	
  NMT [***]%

  	
   

  	
  [***](2)

  
	
  [***] by [***](5)

  	
   

  	
  None

  	
   

  	
  NMT [***]%

  	
   

  	
  [***](2)

  
	
  [***](5)

  	
   

  	
  NLT [***]%

  	
   

  	
  NLT [***]%

  	
   

  	
  [***](2)

  

 

	
  SPEC-111, Rev. 10

  	
  Effective: 18 Jun 2010

  	
  Page 1 of 5

  

 

***Confidential
Treatment Requested 

 

6

 

[Amylin logo]

 

Title:  Specification for AC2993 Drug Substance
(Bachem)

 

Corporate Specification for AC2993
Drug Substance, Supplier: Bachem

 

Description:    N/A

 

	
  ATTRIBUTE

  	
   

  	
  ALERT

  LIMIT

  	
   

  	
  SPECIFICATION

  	
   

  	
  METHOD

  
	
  [***] by [***](5)

  	
   

  	
  NMT [***]%

  	
   

  	
  NMT [***]%

  	
   

  	
  [***](2)

  
	
  [***](5)

  	
   

  	
  None

  	
   

  	
  NMT [***]%

  	
   

  	
  [***](2)

  
	
  [***](5)

  	
   

  	
  None

  	
   

  	
  NMT [***]%

  	
   

  	
  [***](2)

  
	
  [***](5)

  	
   

  	
  None

  	
   

  	
  NMT [***]%

  	
   

  	
  [***](2)

  
	
  [***](5)

  	
   

  	
  None

  	
   

  	
  NMT [***]%

  	
   

  	
  [***](2)

  
	
  [***](5)

  	
   

  	
  None

  	
   

  	
  NMT [***]%

  	
   

  	
  [***](2)

  
	
  [***](5)

  	
   

  	
  None

  	
   

  	
  NMT [***]%

  	
   

  	
  [***](2)

  
	
  [***](5)

  	
   

  	
  None

  	
   

  	
  [***]% - [***]% of [***]

  	
   

  	
  [***](8)

  

 

	
   

  	
   

  	
  Page 2 of 5

  

 

***Confidential
Treatment Requested 

 

7

 

[Amylin logo]

 

Title:  Specification for AC2993 Drug Substance
(Bachem)

 

Corporate Specification for AC2993
Drug Substance, Supplier: Bachem

 

Description:    N/A

 

	
  ATTRIBUTE

  	
   

  	
  ALERT

  LIMIT

  	
   

  	
  SPECIFICATION

  	
   

  	
  METHOD

  
	
  [***]

  	
   

  	
  None

  	
   

  	
  NMT [***]% ([***])

  	
   

  	
   

  
	
  [***]

  	
   

  	
  None

  	
   

  	
  NMT [***]% ([***])

  	
   

  	
  [***](2)

  
	
  [***]

  	
   

  	
  None

  	
   

  	
  NMT [***]% ([***])

  	
   

  	
  [***](2)

  
	
  [***]

  	
   

  	
  None

  	
   

  	
  NMT [***]% ([***])

  	
   

  	
   

  
	
  [***](6)

  	
   

  	
  [***] ppm

  	
   

  	
  Not required

  	
   

  	
  [***]

  
	
  [***](6)

  	
   

  	
  [***]/mg

  	
   

  	
  Not required

  	
   

  	
  [***]

  
	
  [***]

  	
   

  	
  None

  	
   

  	
  [***]/g

  	
   

  	
  [***](9)

  
	
  [***](6)

  	
   

  	
  Report Results

  	
   

  	
  Not required

  	
   

  	
  [***](2)

  
	
  [***](6)

  	
   

  	
  Report Results

  	
   

  	
  Not required

  	
   

  	
  [***](7)

  

 

(1) [***]

(2) [***]

(3) [***]

(4) [***]

(5) [***]

(6) [***]

(7) [***]

(8) [***]

(9) [***]

 

NMT = Not more than

NLT = Not less than

 

Storage Temperature:        Store at NMT [***]

Shipping Temperature:      Ship at NMT [***]

Retest period:                       [***]

 

	
   

  	
   

  	
  Page 3 of 5

  

 

***Confidential
Treatment Requested 

 

8

 

[Amylin logo]

 

Title:  Specification for AC2993 Drug Substance
(Bachem)

 

Corporate Specification for AC2993
Drug Substance, Supplier: Bachem

 

Description:    N/A

 

	
  ATTRIBUTE

  	
   

  	
  SPECIFICATION

  	
   

  	
  METHOD

  
	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***](1)

  
	
  [***]

  	
   

  	
   

  
	
  [***]

  	
   

  	
  [***] mole ratio

  	
   

  	
   

  
	
  [***]

  	
   

  	
  [***] mole ratio

  	
   

  	
   

  
	
  [***]

  	
   

  	
  [***] mole ratio

  	
   

  	
   

  
	
  [***]

  	
   

  	
  [***] mole ratio

  	
   

  	
   

  
	
  [***]

  	
   

  	
  [***] mole ratio

  	
   

  	
   

  
	
  [***]

  	
   

  	
  [***] mole ratio

  	
   

  	
   

  
	
  [***]

  	
   

  	
  [***] mole ratio

  	
   

  	
   

  
	
  [***]

  	
   

  	
  [***] mole ratio

  	
   

  	
  [***](1)

  
	
  [***]

  	
   

  	
  [***] mole ratio

  	
   

  	
   

  
	
  [***]

  	
   

  	
  [***] mole ratio

  	
   

  	
   

  
	
  [***]

  	
   

  	
  [***] mole ratio

  	
   

  	
   

  
	
  [***]

  	
   

  	
  [***] mole ratio

  	
   

  	
   

  
	
  [***]

  	
   

  	
  [***] mole ratio

  	
   

  	
   

  
	
  [***]

  	
   

  	
  [***] mole ratio

  	
   

  	
   

  
	
  [***]

  	
   

  	
  [***] mole ratio

  	
   

  	
   

  
	
  [***]

  	
   

  	
  [***] mole ratio

  	
   

  	
   

  
	
  [***] by [***]

  	
   

  	
  [***] ± [***]

  	
   

  	
  [***](2)

  
	
  [***] by [***]

  	
   

  	
  Consistent with reference
  standard

  	
   

  	
  [***](1)

  
	
  [***]

  	
   

  	
  NMT [***]%

  	
   

  	
  [***](1)

  
	
  [***]

  	
   

  	
  NMT [***]%

  	
   

  	
  [***](3)

  
	
  [***] by [***]

  	
   

  	
  NLT [***]%

  	
   

  	
  [***](1)

  
	
  [***] by [***]

  	
   

  	
  NMT [***]%

  	
   

  	
  [***](1)

  
	
  [***] by [***]

  	
   

  	
  NMT [***]%

  	
   

  	
  [***](1)

  
	
  [***] by [***]

  	
   

  	
  NMT [***]%

  	
   

  	
  [***](1)

  
	
  [***] by [***]

  	
   

  	
  NMT [***]%

  	
   

  	
  [***](1)

  
	
  [***] by [***]

  	
   

  	
  NMT [***]%

  	
   

  	
  [***](1)

  
	
  [***] by [***]

  	
   

  	
  NMT [***]%

  	
   

  	
  [***](1)

  
	
  [***] by [***]

  	
   

  	
  NMT [***]%

  	
   

  	
  [***](1)

  

 

	
   

  	
   

  	
  Page 4 of 5

  

 

Title:  Specification for AC2993 Drug Substance
(Bachem)

 

***Confidential
Treatment Requested 

 

9

 

[Amylin logo]

 

Corporate Specification for AC2993
Drug Substance, Supplier: Bachem

 

Description:    N/A

 

	
  ATTRIBUTE

  	
   

  	
  SPECIFICATION

  	
   

  	
  METHOD

  
	
  [***] by [***]

  	
   

  	
  NMT [***]%

  	
   

  	
  [***](1)

  
	
  [***] by [***]

  	
   

  	
  NMT [***]%

  	
   

  	
  [***](1)

  
	
  [***] by [***]

  	
   

  	
  NMT [***]%

  	
   

  	
  [***](1)

  
	
  [***] by [***]

  	
   

  	
  NMT [***]%

  	
   

  	
  [***](1)

  
	
  [***] by [***]

  	
   

  	
  NMT [***]%

  	
   

  	
  [***](1)

  
	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***](4)

  
	
  [***]

  	
   

  	
  NMT [***]% ([***])

  	
   

  	
   

  
	
  [***]

  	
   

  	
  NMT [***]% ([***])

  	
   

  	
  [***](1)

  
	
  [***]

  	
   

  	
  NMT [***]% ([***])

  	
   

  	
  [***](1)

  
	
  [***]

  	
   

  	
  NMT [***]% ([***])

  	
   

  	
   

  
	
  [***]

  	
   

  	
  NMT [***]/g

  	
   

  	
  [***](5)

  

 

(1) [***]

(2) [***]

(3) [***]

(4) [***]

(5) [***]

 

NMT = Not more than

NLT = Not less than

 

END OF DOCUMENT

 

	
   

  	
   

  	
  Page 5 of 5

  

 

***Confidential
Treatment Requested 

 

10Exhibit 10.1

 

DIVIDEND
REINVESTMENT PLAN

 

OF

 

ARES
CAPITAL CORPORATION

 

effective as of December 13, 2010

 

Ares
Capital Corporation, a Maryland corporation (the “Corporation”), hereby adopts
the following plan (the “Plan”) with respect to the cash portion of dividends
and distributions (collectively, “Cash Dividends”) declared by its Board of
Directors (the “Board of Directors”) on shares of its common stock, par value
$0.001 per share (the “Common Stock”):

 

1.             Unless a registered stockholder (a
“stockholder”) specifically elects to receive cash as set forth below, all Cash
Dividends shall be payable in shares of the Common Stock of the Corporation,
and no action shall be required on such stockholder’s part to receive a
distribution in stock.

 

2.             Such Cash Dividends shall be
payable on such date or dates as may be fixed from time to time by the Board of
Directors to stockholders of record at the close of business on the record date(s) established
by the Board of Directors for the Cash Dividend involved.

 

3.             The Corporation intends to use
primarily newly issued shares of its Common Stock to implement the Plan,
whether its shares are trading at a premium or at a discount to net asset
value.  However, the Corporation reserves
the right to purchase shares in the open market in connection with its
obligations under the Plan.  The number
of shares to be delivered to a stockholder shall be determined by dividing the
total dollar amount of the Cash Dividend payable to such stockholder by the
market price per share of the Corporation’s Common Stock on the valuation date
fixed by the Board of Directors for such Cash Dividend.  Market price per share on a particular date
shall be the closing price for such shares on The NASDAQ Global Select Market on
such date or, if no sale is reported for such day, at the average of their
reported bid and asked prices.

 

4.             A stockholder may, however, elect
to receive any Cash Dividends in cash. 
To exercise this option, such stockholder shall notify The Bank of New
York Mellon, the plan administrator (the “Plan Administrator”), in writing, by
telephone or over the Internet (pursuant to the instructions in Section 10
hereof) so that such notice is received by the Plan Administrator no later than
1:00 p.m. Eastern time on the record date fixed by the Board of Directors
for the Cash Dividend involved.

 

5.             The Plan Administrator will set up a
Plan account for shares acquired pursuant to the Plan for each stockholder who
has not so elected to receive Cash Dividends in cash (each a “Participant”).  The Plan Administrator may hold each
Participant’s shares, together with the shares of other Participants, in
non-certificated form in the Plan Administrator’s name or that of its nominee.

 

 

 

 

6.             The Plan Administrator will confirm
to each Participant each acquisition made pursuant to the Plan as soon as
practicable.  Each Participant may from
time to time have an undivided fractional interest (computed to four decimal
places) in a share of Common Stock of the Corporation and dividends and
distributions on fractional shares will be credited to each Participant’s Plan
account.

 

7.             The Plan Administrator will forward
to each Participant any Corporation-related proxy solicitation materials and
each Corporation report or other communication to stockholders and will vote
any shares held by it under the Plan in accordance with the instructions set
forth on proxies returned by Participants to the Corporation.

 

8.             In the event that the Corporation
makes available to its stockholders rights to purchase additional shares or
other securities, the shares held by the Plan Administrator for each
Participant under the Plan will be added to any other shares held by the
Participant (in book-entry or certificated form) in calculating the number of
rights to be issued to the Participant.

 

9.             The Plan Administrator’s service
fee, if any, and expenses for administering the Plan will be paid for by the
Corporation.

 

10.           Each Participant may terminate his or
its account under the Plan by so notifying the Plan Administrator via the Plan
Administrator’s website at www.bnymellon.com/shareowner/equityaccess, by
filling out the transaction request form located at the bottom of the
Participant’s statement and sending it to P.O. Box 358035, Pittsburgh, PA
15252-8035 or by calling the Plan Administrator’s hotline at 1-866-365-2497.  Such termination will be effective
immediately if the Participant’s notice is received by the Plan Administrator
prior to any dividend or distribution record date; otherwise, such termination
will be effective only with respect to any subsequent dividend or
distribution.  The Plan may be terminated
by the Corporation upon notice in writing mailed to each Participant at least
30 days prior to any record date for the payment of any dividend or
distribution by the Corporation.

 

11.           Upon any termination of the Plan by
the Corporation or by a Participant of his or its account under the Plan, the
Plan Administrator will cause full and fractional shares held for the
Participant under the Plan to be credited to the Participant in book-entry form
with the Corporation’s transfer agent. 
In advance of such termination, a Participant may instead elect to have
the Plan Administrator sell part or all of the Participant’s shares and remit
the proceeds to the Participant, in which case the Plan Administrator will be
authorized to deduct a fee of up to $15 plus $0.12 per share from the
proceeds.  A sale request that is
received before 1:00 p.m. Eastern time, will, subject to market conditions
and their factors, generally be sold the same business day.  Sales usually take place on a daily basis
during trading days on The NASDAQ Global Select Market and are generally
processed on the day that a sale request is received by the Plan Administrator
(if received during a trading day) and no later than five business days of the
receipt of that request.

 

2

 

12.           These terms and conditions may be
amended or supplemented by the Corporation at any time but, except when
necessary or appropriate to comply with applicable law or the rules or
policies of the Securities and Exchange Commission or any other regulatory
authority, only by mailing to each Participant appropriate written notice at
least 30 days prior to the effective date thereof.  The amendment or supplement shall be deemed
to be accepted by each Participant unless, prior to the effective date thereof,
the Plan Administrator receives written notice from the Participant of the
termination of such Participant’s account under the Plan.  Any such amendment may include an appointment
by the Plan Administrator, in its place and stead, of a successor agent under
these terms and conditions, with full power and authority to perform all or any
of the acts to be performed by the Plan Administrator under these terms and
conditions.  Upon any such appointment of
any agent for the purpose of receiving dividends and distributions, the
Corporation will be authorized to pay to such successor agent, for each
Participant’s account, all dividends and distributions payable on shares of the
Corporation held in the Participant’s name or under the Plan for retention or
application by such successor agent as provided in these terms and conditions.

 

13            The Plan Administrator will at all
times act in good faith and use its commercially reasonable best efforts to
ensure its full and timely performance of all services to be performed by it
under this Plan and to comply with applicable law, but assumes no
responsibility and shall not be liable for loss or damage due to errors unless
such error is caused by the Plan Administrator’s negligence, bad faith, or
willful misconduct or that of its employees or agents.

 

14.           These terms and conditions shall be
governed by the laws of the State of New York, including without limitation, Section 5-1401
of the New York General Obligations Law.

 

3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00180-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00180-of-00352.parquet"}]]